Therapeutical targets for revert liver fibrosis;Blancos terapéuticos potenciales para revertir la cirrosis hepática

Revista Medica de Chile

Volumn 135, Issue 6, 2007, Pages 783-791

  García B, Leonel ^a   Gálvez Gastélum, Francisco Javier ^a,b   Armendáriz B, Juan ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b NONE

Author keywords

Fatty liver; Fibrosis; Liver cirrhosis

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CLINICAL TRIAL; DISEASE MODEL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; LIVER; LIVER CIRRHOSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; HUMANS; LIVER; LIVER CIRRHOSIS; PLATELET-DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548301079     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. GRESSNER A, BACHEM M. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 1990; 10: 30-46.
2. GRESSNER A, BACHEM M. Molecular mechanism of liver fibrogenesis: a homage to the role of activated fat-storing cells. Digestion 1995; 56: 335-46.
3. SENTÍES-GÓMEZ D, GÁLVEZ- GASTELUM FJ, ARMENDÁRIZ-BORUNDA J. Fibrosis hepática: el papel de las metaloproteinasas y TGF-B. Gac Med Mex 2005; 141: 307-14.
4. BATALLER R, BRENNER DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
5. OLASO E, FRIEDMAN S. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998; 29: 836-47.
6. LOTERSZTAJN S, JULIEN B, TEIX-CLERC F, GRENARD P, MALLAT A. Hepatic fibrosis: molecular mechanism and drug targets. Annu Rev Pharmacol Toxicol 2005; 45: 605-28.
7. SENOO H. Structure and function of hepatic stellate cells. Med Electron Microsc 2004; 37: 3-15.
8. FORBES S, RUSSO FP, REY V, BURRA P, RUGGE M, WRIGHT NA ET AL. A significant proportion of myofibroblast are bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955-64.
9. BABASA S. Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol 2004; 40: 255-60.
10. TITOS E. Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in ral kupffer cells: implications for liver fibrosis. FASEB J 2003; 17: 1745-47.
11. NELSON D, LAUWERS G, IAU J. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonrespponders. Gastroenterology 2000; 118: 655-60.
12. SHIRATORI Y, IMAZEKI F, MORIYAMA M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
13. HAMMEL P, COUVELARD A, O'TOOLE D. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duc. N Engl J Med 2001; 344: 418-23.
14. PARES A, CABALLERIA J, BRUGUERA M. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986; 2: 3-42.
15. RAMM G, CRAWFORD D, POWELL L. Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J Hepatol 1997; 26: 584-92.
16. SCHILSKY M, SCHEINBERG I, STERNLIEB I. Prognosis of wilsonian chronic active hepatitis. Gastroenterology 1991; 100: 762-7.
17. PAROLA M, LEONARDUZZI G, BIASI F. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology 1992; 16: 1014-21.
18. DE LA MAZA M. Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J Am Coll Nutr 1995; 14: 192-6.
19. MA X, ZHAO J, LIEBER C. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regresión. J Hepatol 1996; 24: 604-13.
20. MIZOBUSHI Y, SHIMIZU I, YASUDA M. Retinyl palmitate reduces hepatic fibrosis in rats induced by dimethylnitrosamine or pig serum. J Hepatol 1998; 29: 933-43.
21. GODICHAUD S, KRISA S, COURONNE B. Deactivation of cultured human liver myofibroblast by transresveratrol, a grapevine-derived polyphenol. Hepatology 2000; 31: 922-31.
22. SUMMERSKILL W, KORMAN M, AMMON H. Prednisone for chronic active liver disease: dose tritration, standart dose, and combination with azathioprine compared. Gut 1975; 16: 876-83.
23. CZAJA A, AMMON H, SUMMESKILL W. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78: 518-23.
24. DAVIS G, CZAJA A, LUDWING J. Development and prognosis of histologic cirrosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 1222-27.
25. YONEYAMA K. Efficacy and safety of prednisolone in patients with autoimmune hepatitis. Adv Ther 2006; 23: 74-91.
26. MANZINI R, BENEDETTI A, JEZEQUEL A. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Arch 1994; 424: 25-31.
27. BRUCK R, HERSHKOVIZ R, LIDER O. The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury. Yale J Biol Med 1997; 70: 391-402.
28. RYHANEN L, STENBACK F, ALA-KOKKO L. The effect of malotilate on type III and type IV collagen, laminin and fibronectin metabolism in dimethylnitrosamine-induced liver fibrosis in the rat. J Hepatol 1996; 24: 238-45.
29. SHIMIZU I, MA Y, MIZOBUCHI Y. Effects of Sho-saikoto, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-60.
30. MIYAMURA M, ONO M, KYOTANI S. Effects of sho-saikoto extracts on fibrosis and regeneration of the liver in rats. J Pharm Pharmacol 1998; 50: 97-105.
31. HERNÁNDEZ-CAÑAVERAL I, GONZÁLEZ J, LÓPEZ-CASILLAS F, ARMENDARIZ-BORUNDA J. Amplified expression of dominant-negative transforming growth fatctorbeta type II receptor inhibits collagen type I production via reduced Smad-3 activity. J Gastroenterol Hepatol 2004; 19: 380-7.
32. GÁLVEZ-GASTELUM FJ, SANDOVAL-RODRÍGUEZ A, ARMENDÁRIZ-BORUNDA J. El factor de crecimiento transformante ß como blanco terapéutico. Sal Pub Mex 2004; 46: 341-50.
33. SAKAIDA I, UCHIDA K, HIROKANA K. Prolyl 4-hidroxylase inhibitor (HOE 077) prevents TIMP-1 gene expresión in rat liver fibrosis. J Gastroenterol 1999; 34: 376-7.
34. SAKAIDA I, MATSUMURA Y, KUBOTA M. The prolilbb 4-hidroxylase inhibitor HOE 077 prevents activation of Ito cells, reducing procollagen gene expresión in rat liver fibrosis induced by choline-deficient L-amino acid-defined diet. Hepatology 1996; 23: 755-63.
35. BICKEL M, BARINGHAUS K, GERL M. Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hidrocylase inhibitor. Hepatology 1998; 28: 404-11.
36. WANG Y, WANG S, BICKEL M. Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol 1998; 152: 279-87.
37. NAGLER A, GOFRIT O, OHANA M. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol 2000; 164: 1776-80.
38. PINES M, KNOPOV V, GENINA O. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine- induced liver cirrosis. J Hepatol 1997; 27: 391-8.
39. HARRIS E, KRANE S. Effects of colchicines on collagenase in cultures of rheumatoid synovium. Arthritis Rheum 1971; 14: 669-84.
40. DIEGELMANN R, PETERKOFFSKY B. Inhibition of collagen secretion from bone and culture fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci 1972; 69: 892-6.
41. ROJKIND M, KERSHENOBICH D. Effect of colchicine on collagen, albumin and transferrin sintesis by cirrhotic rat liver slices. Biochim Biophys Acta 1975; 378: 415-23.
42. KERSHENOBICH D, VARGAS F, GARCÍA- TSAO G. Colchicina in the treatment of cirrosis of the liver. N Engl J Med 1988; 318: 1709-13.
43. BODENHEIMER H, SCHAFFNER F, PEZZULLO J. Evaluation of colchicine therapy in primary biliary cirrosis. Gastroenterology 1988; 95: 124-9.
44. KAPLAN M, ALLING D, ZIMMERMAN H. A prospective trial of colchicine for primary biliary cirrosis. N Engl J Med 1986; 315: 1448-54.
45. WARNES T, SMITH A, LEE F. A controlled trial of colchicines in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol 1987; 5: 1-7.
46. PREAUX A, MALLAT A, ROSENBAUM J. Pentoxifylline inhibits growth and collagen synthesis of cultured human hepatic myofibroblast-like cells. Hepatology 1997; 26: 315-22.
47. PINZANI M, MARRA F, CALIGIURI A. Inhibition by pentoxifylline of extra-cellular signal-regulated kinase activation by platelet-derived growth factor in hepatic stellate cells. Br J Pharmacol 1996; 119: 1117-24.
48. WINDMEIER C, GRESSNER A. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997; 29: 181-96.
49. SVEGLIATI-BARONI G, DI SARIO A, CASINI A. The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hapatic stellate cells. J Hepatol 1999; 30: 868-75.
50. BORKHAM-KAMPHROST E, STOLL D, GRESSNER A, WEISKIRCHEN R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrosis. BBRC 2004; 321: 413-23.
51. REIF S, WEIS B, AEED H. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrosis in rats. J Hepatol 1999; 31: 1053-61.
52. JONSON J, CLOUSTON A, ANDO Y, KELEMER L, HORN M, ADAMSON M ET AL. Angiotensin converting enzyme inhibition attenuates the development of hepatic fibrosis in the rat bile duct ligation model. Hepatology 2000; 32: 191.
53. MARGOLIN S, LEFKOWITZ S. Pirfenidone: a novel pharmacologic agent for prevention and resolution (removal) of lung fibrosis. FASEB J 1994; 8: A117.
54. GARCÍA L, HERNÁNDEZ I, SANDOVAL A, SALAZAR A, GARCÍA J, VERA J ET AL. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002; 37: 797-805.
55. MIRANDA-DÍAZ A, RINCON AR, SALGADO S, VERA-CRUZ J, GÁLVEZ J, ISLAS MC ET AL. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis. Mol Ther 2004; 9: 30-7.
56. SALGADO S, GARCÍA J, VERA J, SILLER F, BUENO M, MIRANDA A ET AL. Liver cirrosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000; 2: 545-51.
57. IIMURO Y, NISHIO T, MORIMOTO T, NITTA T, STEFANOVIC B, CHOI SK ET AL. Delivery of matriz metalloproteinase-1 attenuates established liver fibrosis in the rat. J Clin Invest 2001.
58. SILLER-LÓPEZ F, SANDOVAL A, SALGADO S, SALAZAR A, BUENO M, GARCÍA J ET AL. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004; 126: 1122-33.
59. GARCÍA-BAÑUELOS J, SILLER-LÓPEZ F, MIRANDA A, AGUILAR LK, AGUILAR-CÓRDOVA E, ARMENDARIZ-BORUNDA J. Cirrhotic rat livers with extensive fibrosis can be safety transduced with clinical grade adenoviral vectors. evidence of cirrhosis reversion. Gen Ther 2002; 9: 127-34.
60. PROSSER C, YEN RD, WU J. Molecular therapy for hepatic injury and fibrosis: where are we? World J Gastroenterol 2006; 12: 509-15.
61. GÁLVEZ-GASTELUM FJ, SEGURA A, GARCÍA J, BEAS C, ARMENDARIZ-BORUNDA J. Combined HUPA plus MMP8 gene therapy reverts cirrhosis and improves hepatic encephalopathy. Gut 2004; 53: A259-A260.